IKNA: Ikena Oncology Amount of Cash per Share

Corporate emblem and logo of Ikena Oncology Inc. (IKNA)

The oncology sector is traditionally considered a defensive asset due to stable demand for medical services. The cash per share trend reflects the current state of liquidity, where the parameter value equals 23.80. The prospects for Ikena Oncology, Inc. (IKNA) rely on the development of targeted drugs for rare mutations and the use of production outsourcing via US CMOs to minimize infrastructure risks.

IKNA Ikena Oncology: Cash Funds per Share in the range 07/04/2022 - 08/09/2025

Analytical breakdowns for Ikena Oncology, Inc.

- price and consensus price forecast:
- market capitalization information:
- cash position and cash flow details:
Comprehensive company analysis:Ikena Oncology Inc.
Signature product of Ikena Oncology

This metric reflects the volume of liquid assets per common share, determining the internal protection of capital. For Ikena Oncology, Inc. (IKNA), this reserve is critical for financing the development of the IK-930 inhibitor and solid tumor therapies. By analyzing the cash per share forecast, an investor assesses the company's autonomy from external loans. Excess liquidity guarantees survival during clinical trials; however, an excessive cushion may signal inefficient capital management.

Analysis of competing companies

Cash Funds per Single Share ONC (BeiGene Corp)|Cash per Single Share HALO (Halozyme Therapeutics, Inc.)|Cash per Share Revolution Medicines, Inc. (RVMD)|Cash per Share AAPG (ascentage.com)|CG Oncology Inc (CGON) - Cash on Hand per Share|URGN - Cash Funds per Share|Bicara Bio - Cash Calculated per Single Share|PSNL: Cash per Share|Cash Funds per Single Share ERAS|Cash per Single Share DCTH|Cash on Hand per Share Y-mAbs Therapeutics Inc YMAB|Cash per Share AURA|CADL (Candel Therapeutics, Inc.) - Amount of Cash per Share|Cash Funds per Share Accuray Inc ARAY|Cash Funds Calculated per Share SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Cash per Share|Cash on Hand per Share Citius Oncology|HURA: Cash per Share|Cash Money per Share TARA (Protara)|FATE (fatetherapeutics.com) - Cash per Share|Cash on Hand per Share Aadi Bioscience WHWK|Cash per Share TCRX|CSBR - Cash on Hand per Share|XBiotech - Cash per Single Share|CEL-SCI Corporation (CVM) - Cash on Hand per Share|OSTX - Cash Funds per Share|Cash on Hand per Share Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Cash per Single Share|ANL (Adlai Nortye Ltd) - Cash Funds per Share|Cash per Single Share VERU|Tempest Therapeutics (TPST) - Cash Funds Calculated per Share|Cash per Share XLO|Cash per Single Share Renovaro RENB|Cash per Share MURA (Mural Oncology PLC)|KAPA - Cash per Single Share|OnKure Therapeutics - Cash per Share|w2.cytomed.sg - Cash Calculated per Single Share|Curis Corp (CRIS) - Cash Funds per Share|Cash on Hand per Share Apollomics Corp (APLM)|Cash Funds per Share Tharimmune|Cash per Share advanbiomed.com|Cash Funds per Share Genprex, Inc (GNPX)|Cash Funds Calculated per Share Calidi Biotherapeutics, Inc.|Cash per Share SBFM (Sunshine Biopharma Inc.)|XBIO - Cash per Single Share|SLRX: Cash per Single Share|Amount of Cash per Share PPBT (Purple Biotech Ltd.)|AONC: Cash per Share|Cash on Hand per Share BeOne Medicines (BGNE)|Cash Funds per Share Checkpoint Therapeutics, Inc.|Cash per Single Share Elevation Oncology (ELEV)|Cash Funds per Share iCAD Corp (ICAD)|NTBL (Notable Labs) - Amount of Cash per Share|Cash per Share VIRX (Viracta Therapeutics)|Cash Funds Calculated per Share MorphoSys AG (MOR)|NAYA Biosciences Corp - Cash per Share|Cash on Hand per Share ascentage.com